Pharma: Clinic Roundup

• Teva Pharmaceuticals Ltd., of Jerusalem, reported findings from four Phase III trials showing that QNASL (beclomethasone dipropionate), a nasal aerosol corticosteroid, produced a significant change from baseline weekly averages of the subject-reported 24-hour reflective nasal symptom scores (rTNSS) over the first 30 weeks of treatment in patients with seasonal allergic rhinitis and perennial allergic rhinitis.